4-(((1r,4r)-4-aminocyclohexyl)oxy)benzoic acid | 1394012-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(((1r,4r)-4-aminocyclohexyl)oxy)benzoic acid
• 英文别名: 4-((trans-4-aminocyclohexyl)oxy)benzoic acid；4-[(trans-4-aminocyclohexyl)oxy]benzoic acid；trans-4-[(4-aminocyclohexyl)oxy]benzoic acid；4-(trans-4-aminocyclohexyloxy)benzoic acid；trans-4-(4-aminocyclohexyloxy)benzoic acid；4-[(4-aminocyclohexyl)-oxy]benzoic acid
• CAS: 1394012-10-2
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: PEYPACVGIXCFCU-UMSPYCQHSA-N

物化性质

• 沸点：
  401.8±35.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.03
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.55
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4-(((1r,4r)-4-aminocyclohexyl)oxy)benzoic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-N-methylbenzamide
  参考文献：
  名称：

  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

  摘要：

  To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.011
• 作为产物：
  描述：

  对氟苯腈 在 sodium hydride 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.0h， 生成 4-(((1r,4r)-4-aminocyclohexyl)oxy)benzoic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

  摘要：

  To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.011

文献信息

• Sulfur(VI) fluoride compounds and methods for the preparation thereof
  申请人：The Scripps Research Institute

  公开号：US10117840B2

  公开（公告）日：2018-11-06

  This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

  该应用描述了由式(I)表示的化合物：(I)其中：Y是一个生物活性有机核心基团，包括芳基、杂芳基、非芳香烃基和非芳香杂环基中的一个或多个，其中Z与之以共价键结合；n为1、2、3、4或5；m为1或2；Z为O、NR或N；X1为共价键或—CH2CH2—，X2为O或NR；R包括H或从芳基、杂芳基、非芳香烃基和非芳香杂环基中选择的取代或未取代基团。还描述了制备这些化合物的方法、使用这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] SORAFENIB DERIVATIVES AS sEH INHIBITORS<br/>[FR] DÉRIVÉS DE SORAFÉNIB UTILISÉS EN TANT QU'INHIBITEURS DE LA SEH
  申请人：UNIV CALIFORNIA

  公开号：WO2012112570A1

  公开（公告）日：2012-08-23

  The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

  本发明提供了用于抑制可溶性环氧化物水解酶及相关疾病状况的化合物。
• Synthesis and Properties of 1,3-Disubstituted Ureas and Their Isosteric Analogs Containing Polycyclic Fragments: V. 1-(Bicyclo[2.2.1]heptan-2-yl)-3-R- and 1-(1,7,7-Tricyclo[2.2.1]heptan-2-yl)-3-R-ureas
  作者：D. A. Pitushkin、V. V. Burmistrov、M. H. Abbas Saeef、A. A. Vernigora、G. M. Butov

  DOI：10.1134/s1070428020110020

  日期：2020.11

  Abstract A series of 1,3-disubstituted ureas containing a bicyclic lipophilic group of natural origin were synthesized by the reactions of bicyclo[2.2.1]heptane-2-yl isocyanate with amines in yields of up to 82% and by the reactions of bicyclo[2.2.1]heptan-2-amine and 1,7,7-trimethylbicyclo[2.2.1]heptan-2-amine with 1,1'-carbonyldiimidazole in yields of up to 94%. The synthesized ureas are potent inhibitors

  摘要 通过双环[2.2.1]庚烷-2-基异氰酸酯与胺的反应，合成产率最高为82％的一系列含有天然双环亲脂性基团的1,3-二取代脲，并通过双环反应[2.2.1]庚-2-胺和1,7,7-三甲基双环[2.2.1]庚-2-胺与1,1'-羰基二咪唑的产率高达94％。合成的脲是RNA病毒复制和可溶性环氧化物水解酶的有效抑制剂。
• [EN] FLUOROSULFONYL sEH INHIBITORS<br/>[FR] INHIBITEURS DE SEH SUBSTITUÉS PAR FLUOROSULFONYLE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015188060A1

  公开（公告）日：2015-12-10

  Fluorosulfonyl-substituted sEH inhibitors are compounds represented by Formula (I): wherein R1 is selected from the group consisting of alkyl, heteroalkyi, C5-C12 cycloalkyi, C5-C12 cycloalkylalkyi, C5-C12 cycloalkylheteroalkyi, arylalkyi, arylheteroalkyi, aryl, and heteroaryl; and R1 can be substituted or unsubstituted; P1 is a primary pharmacophore; P2 is a secondary pharmacophore; P3 is a tertiary pharmacophore; and L1 and L2 are linking groups. The subscript m has a value of 0 or 1; n has a value of 0 or 1; and the compound of Formula (I) includes at least one S02F ("fluorosulfonyl") group covalently bonded thereto.

  氟磺酰基取代的sEH抑制剂是由式(I)代表的化合物：其中R1选自烷基、杂原烷基、C5-C12环烷基、C5-C12环烷基烷基、C5-C12环烷基杂原烷基、芳基烷基、芳基杂原烷基、芳基和杂原芳基组成；R1可以是取代或未取代的；P1是一级药效团；P2是二级药效团；P3是三级药效团；L1和L2是连接基。下标m的值为0或1；n的值为0或1；式(I)的化合物至少包含一个与之共价键合的S02F（"氟磺酰基"）基团。
• Synthesis of Bicyclic Isocyanates and Bioisosteric 1,3-Disubstituted Ureas as Soluble Epoxide Hydrolase Inhibitors
  作者：V. V. Burmistrov、V. S. D’yachenko、E. V. Rasskazova、G. M. Butov

  DOI：10.1134/s1070428019080165

  日期：2019.8

  7-trimethyl-2-oxabicyclo[2.2.1]heptan-3-one and 2-isocyanatobicyclo[2.2.1]-hept-5-ene were prepared by the Curtius rearragement reaction from the corresponding carboxylic acids. The synthesized isocyanates were used to synthesize, in high yields of 74–93%, bioisosteric 1,3-disubstituted ureas as potential human soluble epoxide hydrolase inhibitors.

  由库尔蒂乌斯制备了（1 S）-1-异氰酸根-4,7,7-三甲基-2-氧杂双环[2.2.1]庚-3--和2-异氰酸根双环[2.2.1]-庚-5-烯相应的羧酸进行重排反应。合成的异氰酸酯用于高产率地合成74-93％的生物立体异构的1,3-二取代尿素，作为潜在的人类可溶性环氧化物水解酶抑制剂。